On December 19, 2024, Recursion Pharmaceuticals, Inc. based in Salt Lake City, Utah, disclosed that the Compensation Committee of its Board of Directors sanctioned the allocation of inducement restricted stock unit (RSU) awards. These awards encompass 7,952,836 shares of its class A common stock and were designated for 230 new employees. This action was taken under Recursion's 2024 Inducement Equity Incentive Plan. The RSUs were granted to new employees upon their commencement of employment with a subsidiary of Recursion as part of the company's acquisition of Exscientia plc. This move adhered to Nasdaq Listing Rule 5635(c)(4) regarding inducement grants.